– Detection of cancer biomarkers within 10 minutes with a single drop of blood
– markB is a point-of-care testing device, that can be used by anyone
– After beginning with cancer diagnosis, markB will address cardiovascular disease and Alzheimer’s disease
– Reduction of time and costs of analysis
SEOUL, South Korea, Aug. 2, 2018 /PRNewswire/ — Jaekyu Choi, CEO of BBB Inc., presented the technology behind markB, a portable cancer analyzer, at the American Association for Clinical Chemistry (AACC) 2018 Annual Scientific Meeting & Clinical Lab Expo.
AACC held its 70th annual meeting, featuring in-vitro diagnostic testing companies from around the world, at one of the largest exhibitions in the field, in Chicago from July 31st until August 2nd.
markB is a POCT (Point-of-Care-Testing) analyzer that detects biomarkers from a single drop of blood drawn from the fingertips. Once blood is loaded onto the cartridge, the analyzer immediately carries out immunoassay to draw a result in 10 minutes.
This technology is based upon two of BBB’s patented technologies: passive plasma separation technology and magnetic force-assisted electrochemical sandwich immunoassay. While the conventional approach of using centrifugation to separate plasma from whole blood takes more than 30 minutes, BBB’s technology allows this to take place instantly. Once the reaction is filled with plasma, the immunoassay process is controlled by magnetic fields. Then, the device quantifies biomarkers by measuring the electrochemical signals from the magnetic nanoprobes.
BBB has drastically improved precision of analysis in point-of-care testing with markB. Furthermore, markB reduces time and cost of analysis while demonstrating equivalent accuracy of hospital equipment.
BBB’s Vice President, Hyundoo Hwang stated: “We have already completed our research on three cancer biomarkers thus far, including that of prostate cancer (PSA), liver cancer (AFP) and colon cancer (CEA). Our research indicates that this technology is applicable to multiple biomarkers.” Hwang also proposed a roadmap for an expansion plan towards cardiovascular diseases and Alzheimer’s disease.
Finally, Hwang stated that: “With this handheld device, diagnosis is not only possible in hospitals, but also in emergency situations and or in individuals’ homes without the assistance of professionals — making point-of-care-testing possible for everyone.”
Following the presentation at AACC, BBB is scheduled to demonstrate markB at MEDICA, World Forum for Medicine, at Dusseldorf, Germany this November.
For more information about BBB, please click here.
BBB is a Korean mobile healthcare startup founded in Oct 2014. The company develops and sells elemark®, an Android-based blood testing device that enables personalized blood tests and biomarker monitoring. Its purview spans the U.S.A., France, South Africa, China, Malaysia, and the U.A.E., among others. with local partners in R&D, production, and sales. After introducing elemark® dual check to the market in Nov 2017, BBB is developing various other IVD solutions such as a cholesterol testing device and lab-on-a-chip technology for cancer diagnosis and prognosis management.
Source: BBB Inc.